Frankfurt - Delayed Quote EUR
OPKO Health, Inc. (XCY.F)
1.1922
-0.0066
(-0.55%)
At close: 9:41:31 PM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 5 |
| Avg. Estimate | 163.13M | 168.53M | 662.52M | 716.28M |
| Low Estimate | 160.5M | 166.7M | 636.5M | 629M |
| High Estimate | 166.3M | 169.8M | 684.8M | 779M |
| Year Ago Sales | 173.69M | 182.2M | 713.1M | 662.52M |
| Sales Growth (year/est) | -6.08% | -7.50% | -7.09% | 8.12% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| XCY.F | -- | -- | -- | -- |
| S&P 500 | 7.01% | 4.85% | 8.55% | 14.15% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/7/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/19/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/12/2025 |
| Maintains | Barrington Research: Outperform to Outperform | 3/12/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/3/2025 |
| Maintains | Barrington Research: Outperform to Outperform | 2/28/2025 |